This AXL Target Evaluation Report is generated from PatSnap MCP data. AXL is a highly active NSCLC resistance and tumor-microenvironment target, but mixed clinical outcomes mean differentiation and patient selection matter more than target popularity.

This MCL1 Target Evaluation Report is generated from PatSnap MCP data. MCL1 has strong apoptosis biology in AML, but the clinical record shows a difficult therapeutic window and multiple terminated programs, making risk management central to any R&D plan.

This USP1 Target Evaluation Report is generated from PatSnap MCP data. USP1 is an early but strategically important DDR target for HRD and BRCA-mutant tumors, especially in combination with PARP inhibition or platinum chemotherapy.

This CHEK1 Target Evaluation Report is generated from PatSnap MCP data. CHK1 is a DNA-damage checkpoint target with meaningful clinical volume and a renewed biomarker angle through ACR-368 / prexasertib and OncoSignature-selected gynecologic cancers.

This ATR Target Evaluation Report is generated from PatSnap MCP data. ATR is one of the most clinically active DNA-damage-response targets, with 126 solid-tumor trials and 86 result records spanning PARP combinations, immunotherapy, ADC concepts, and replication-stress biomarkers.

This WEE1 Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. In ovarian cancer, WEE1 inhibition has moved from DNA-damage checkpoint rationale into Phase 3 competition, led by azenosertib in CCNE1-positive platinum-resistant disease.

This MTAP Target Evaluation Report is generated from PatSnap MCP data. MTAP is best evaluated as a biomarker and synthetic-lethality context rather than a conventional drug target: direct MTAP-mapped drug counts are low, but Clinical Trials MCP found 46 MTAP-deletion trial records and PRMT5-related result records that make the MTAP-loss opportunity clinically important.

This SHP2 Target Evaluation Report is generated from PatSnap MCP data. PTPN11 / SHP2 is a central RAS/MAPK signaling node in NSCLC, with clinical development focused on KRAS G12C combinations, EGFR-mutant resistance, and pathway-feedback suppression.

This SOS1 Target Evaluation Report is generated from PatSnap MCP data. SOS1 is a RAS pathway target with active early clinical competition in KRAS-mutant tumors, but Clinical Trials MCP did not return released result records for the selected SOS1 solid-tumor query, making this a high-interest but still readout-light target.

This WRN Target Evaluation Report is generated from PatSnap MCP data. WRN is an emerging synthetic-lethality target for MSI-H and dMMR tumors, with early clinical programs now testing whether Werner helicase inhibition can convert a strong genetic dependency into a therapeutic class.

This PRMT5 Target Evaluation Report is generated from PatSnap Target & Disease MCP and Clinical Trials MCP data. The report highlights PRMT5 as a clinically active oncology target, especially in MTAP-deleted tumors where MTA-cooperative PRMT5 inhibition has created a differentiated synthetic-lethality strategy.

This CDK2 Target Evaluation Report is generated from PatSnap MCP data. CDK2 is an increasingly important cell-cycle target in breast cancer, especially for HR+/HER2- disease after CDK4/6 inhibitor exposure and for tumors with cyclin E or CCNE1-driven biology.